Neurona Therapeutics is a clinical-stage biotherapeutics company developing regenerative cell therapies that permanently integrate into neural circuits, replace affected cells, and rebalance dysregulated electrical activity to repair the nervous system.

Neurona Therapeutics

Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company’s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders. For more information about Neurona visit our website.

South Carolina Research Authority

National Institutes of Health

California Institute for Regenerative Medicine

California Institute of Regenerative Medicine (CIRM)

The Column Group

Alexsis de Raadt-St. James

Ironfire Ventures

UCB Ventures

Alexandria Venture Investments

Sphera Funds Management

Director of Discovery Research at Neurona, Marina Bershteyn, Ph.D., has been invited to present a seminar titled "Development of allogeneic GABAergic inhibitory interneuron cell therapy for drug-resistant focal epilepsy" at the Cell Based Therapeutics of Brain Diseases Meeting, which is part of the Neuroscience School of Advanced Studies Challenge Workshops. Marina's presentation will outline recent clinical data and supporting preclinical data from Neurona's ongoing clinical trial of NRTX-1001 which is demonstrating the potential to significantly reduce seizure frequency in adults with unilateral mesial temporal lobe epilepsy (MTLE). 
Learn more about NRTX-1001 and our clinical trials here: https://lnkd.in/e37V9uf2
Learn more about the meeting here: https://lnkd.in/eVRp7Wbx

We are delighted to announce that Manher (AJ) Joshi, M.D., has joined Neurona as Chief Medical Officer. AJ brings a wealth of clinical development and commercialization expertise across a variety of neuro-focused indications and has extensive experience in the development of cell therapies. We look forward to his leadership as we advance our pipeline of cellular therapeutic candidates for neurological diseases, including NRTX-1001 for drug-resistant focal epilepsy. Welcome to the Neurona team, AJ!
Learn more about AJ's background here: https://lnkd.in/eMjD7Tvs
#epilepsy #celltherapy

If you are attending the Jefferies Global Healthcare Conference in New York City this week, our CEO, Cory R. Nicholas, PhD, will be hosting meetings to update investors on the most recent data from Neurona's ongoing open-label Phase 1/2 clinical trial of NRTX-1001 in adults with drug-resistant, unilateral mesial temporal lobe epilepsy (MTLE) and the Company's plans to develop its pipeline of allogeneic, off-the-shelf, regenerative neural cell therapy products.
#epilepsy #celltherapy

If you are attending #ASGCT2024 please stop by Poster # 842 on Wednesday, May 8th when Neurona team member Brianna Feld will be presenting supporting preclinical data and the most recent clinical update from our hpsc-derived inhibitory interneuron cell therapy, NRTX-1001, which is being evaluated in an ongoing clinical trial in adults with drug-resistant focal #epilepsy.

At the Annual Meeting of the American Academy of Neurology ,#AAN2024, today, our CEO, Cory R. Nicholas, PhD, is presenting a clinical update on the first cohort of our ongoing Phase I/II clinical trial of NRTX-1001, which is being evaluated in people with drug-resistant focal #epilepsy. Read the details in our press release here: https://lnkd.in/e4yuHJiK

COM:NEURONATHERAPEUTICS

Neurona Therapeutics